Highlights
- Objective response rate (ORR) reached 40% in patients with recurrent gynaecological clear cell carcinoma (CCGC).
- The combination therapy showed efficacy in both ovarian and endometrial clear cell subtypes.
- Responses were observed regardless of prior anti-angiogenic treatment or microsatellite stability status.
- The safety profile was consistent with known toxicities of the combination, primarily hypertension and liver enzyme elevations.
Background: The Clinical Challenge of Clear Cell Gynaecological Carcinoma
